University of California San Francisco

Publications

  1. Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data.
    2025 | PubMed
  2. Characterization of small intestinal neuroendocrine tumorlets.
    2026 | PubMed
  3. Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.
    2026 | PubMed
  4. STAT3 regulates inflammatory cytokine production downstream of TNFR1 by inducing expression of TNFAIP3/A20.
    2022 | PubMed
  5. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    2019 | PubMed
  6. ASO Visual Abstract: Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival.
    2026 | PubMed
  7. Characterization of tumor-associated microbiome in multifocal small intestinal neuroendocrine tumors (SI-NETs).
    2025 | PubMed
  8. 4D-MRI at 0.55T for internal target volume delineation in liver radiation therapy planning.
    2025 | PubMed
  9. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    2020 | PubMed
  10. BIO26-035: Validation of an Electronic Health Record Phenotype for Advanced Solid Cancer Across Five University of California Health Systems.
    2026 | PubMed
  11. Spatial Transcriptomics Reveals Location-Specific Tumor Cell Subtypes and Signaling within Multifocal Small Intestinal Neuroendocrine Tumors.
    2026 | PubMed
  12. Characterization of small intestinal neuroendocrine tumorlets.
    2026 | PubMed
  13. Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms.
    2025 | PubMed
  14. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    2019 | PubMed
  15. Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing.
    2026 | PubMed
  16. Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).
    2025 | PubMed
  17. True Incidence of Appendiceal Neoplasms in Patients Presenting with Complicated Appendicitis: A Call for a Revised Management Algorithm.
    2026 | PubMed
  18. Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.
    2025 | PubMed
  19. Synchronous Versus Metachronous Colorectal Liver Metastasis Yields Similar Survival in Modern Era.
    2020 | PubMed
  20. How to implement DPYD genotyping into practice.
    2026 | PubMed
  21. Video-based assessment identifies intraoperative predictors of clinically relevant POPF following minimally invasive distal pancreatectomy.
    2026 | PubMed
  22. Minimally Invasive Versus Open Resection for Solid Pseudopapillary Tumors of the Pancreas: A Propensity Score-Matched Analysis.
    2025 | PubMed
  23. Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study.
    2025 | PubMed
  24. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    2019 | PubMed
  25. Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.
    2026 | PubMed
  26. ASO Visual Abstract: True Incidence of Appendiceal Neoplasms in Patients Presenting with Complicated Appendicitis: A Call for a Revised Management Algorithm.
    2026 | PubMed
  27. ACR Appropriateness Criteria® Staging and Follow-Up of Pancreatic Neuroendocrine Tumors.
    2026 | PubMed
  28. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    2023 | PubMed
  29. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    2019 | PubMed
  30. Shifts in the human gut microbiome during cancer chemotherapy are diet-dependent.
    2025 | PubMed
  31. Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study.
    2025 | PubMed
  32. Minimally Invasive Distal Pancreatectomy as the Standard of Care in the US: Are We There Yet?
    2025 | PubMed
  33. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).
    2025 | PubMed
  34. RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon.
    2020 | PubMed
  35. BIO26-035: MTAP Deficiency in Thoracic Oncology: Bridging Genomic Loss, Survival Deficits, and Immunosuppressive Microenvironments.
    2026 | PubMed
  36. Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival.
    2026 | PubMed
  37. Patterns of Progression After Peptide Receptor Radiopharmaceutical Therapy.
    2026 | PubMed
  38. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms.
    2025 | PubMed
  39. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    2019 | PubMed
  40. Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction.
    2026 | PubMed